Market revenue in 2022 | USD 916.0 million |
Market revenue in 2030 | USD 1,698.9 million |
Growth rate | 8% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 53.41% in 2022. Horizon Databook has segmented the China hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
China has been facing the issue of a growing death rate owing to the increasing incidence of diseases related to hormonal imbalance. According to an article published by Frontiers in Endocrinology, (May 2021), the prevalence of different types of hyperthyroidism was as follows: severe subclinical hyperthyroidism (0.22%), overt hyperthyroidism (0.78%), graves’ disease (0.53%), and mild subclinical hyperthyroidism (0.22%).
While it was more prevalent in women than men, the prevalence of hypothyroidism was significantly reduced after 60 years. In addition, increased levels of thyroid peroxidase antibody and thyroglobulin levels were significantly related to the rising prevalence of overt hypothyroidism and graves’ disease.
Horizon Databook provides a detailed overview of country-level data and insights on the China hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into China hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account